What happens after Wegovy — from first dose to long-term results

Stage 1: the first few weeks, adjustment, not results

The first pen of Wegovy contains the 0.25 mg starter dose. That number is not a typo. Your prescriber begins here deliberately, because jumping straight to a therapeutic dose produces far more nausea, vomiting and stomach upset than most people can tolerate. The job of the first four weeks is to let your gut adapt to a GLP-1 receptor agonist slowing gastric emptying.

During this phase, appetite suppression is noticeable for some people but modest for most. The scale probably will not move much, and that is expected. What you are likely to notice instead is a change in how food sits with you, smaller amounts feel filling sooner, greasy meals may feel heavier than usual, and nausea after eating is common. These effects are discussed in detail on our page about what happens after your first Wegovy injection.

Practical habit worth building in week one: before each injection, check the pen's expiry date and confirm it has been refrigerated (2–8°C). A quick 30-second check before you cap the needle prevents one of the most avoidable waste errors. Store it correctly and the medicine is fine; leave it on a warm windowsill for a weekend and you may be injecting something that is no longer effective.

Injection-site reactions (redness, mild swelling, a faint itch) are common and almost always short-lived. Rotate sites between abdomen, thigh and upper arm. The alcohol swabs supplied with or alongside your treatment support clean technique at each site.

Stage 2: the titration climb (dose increases every four weeks

Wegovy's licensed titration schedule moves from 0.25 mg through 0.5 mg, 1.0 mg and 1.7 mg, up to the standard 2.4 mg maintenance dose) each step roughly four weeks apart, at your prescriber's direction. The 7.2 mg maintenance dose, approved by the MHRA in April 2026 for adults with a BMI of 30 or above, adds a further option at the top of that ladder, though availability is confirmed at consultation rather than assumed.

Each dose increase tends to bring a brief return of gastrointestinal symptoms (nausea, looser stools, or both) before settling again, usually within a week or two. This is the pattern your clinical team expects. It is not a sign that something has gone wrong; it is the body adjusting again to a higher level of drug exposure.

Weight loss accelerates through this phase for most people. The STEP 1 trial, published in the New England Journal of Medicine, recorded average body-weight reductions of around 15% over 68 weeks at 2.4 mg, alongside lifestyle changes, a figure drawn from a large randomised trial of over 1,900 adults. Individual results vary. Some people lose more, some less; pace differs by person and by dose.

If a dose increase causes side effects that do not settle, a prescriber may hold the current dose for longer before moving up, or discuss whether the top dose is appropriate for you at all. That conversation is with a real clinician, the process is not automated. If you're thinking about what Wegovy costs over this period, our Wegovy cost guide sets out what a realistic monthly budget looks like.

Stage 3: at maintenance dose, what sustained treatment looks like

Most people spend the majority of their treatment time at maintenance dose. Appetite suppression is typically at its strongest here. Energy intake falls not through hunger and willpower but because satiety arrives earlier at each meal. That mechanism (acting on GLP-1 receptors in the gut and brain) is central to how the medicine works, and it does not switch off between doses the way some people expect.

The clinical picture at this stage is broadly stable: weight loss continues or plateaus, side effects are minimal for most people (some experience persistent nausea; others feel almost nothing), and the weekly injection becomes routine. Protein adequacy matters here, reduced appetite can push total intake low enough that muscle is lost alongside fat, which is worth discussing with your prescriber or a dietitian.

NICE recommends semaglutide for a maximum of two years within a specialist weight management framework under NICE technology appraisal TA875. Private prescribers follow clinical guidance; your repeat prescriptions are reviewed each time, not issued automatically. At nume, a clinical review happens before every repeat order, no prescription is renewed as a default.

The Wegovy treatment overview covers eligibility criteria and the licensed indications in full if you want to check where you stand before consulting.

Stage 4: after Wegovy ends, the evidence on what follows

This is the part most people do not read before they start. Weight regain after stopping Wegovy is well-evidenced and clinically significant. Trial data show that a substantial proportion of weight lost during treatment returns within a year of stopping, because the underlying biology that made weight management difficult in the first place is still there. Semaglutide manages the condition; it does not cure it.

What that means practically depends on individual circumstances: some people transition to lifestyle maintenance alone, some move to a different treatment, some restart after a break. None of those routes should be chosen unilaterally. Our page on what happens after you stop taking Wegovy covers the regain evidence in detail, including what the clinical guidance says about planning an exit strategy with your prescriber rather than just stopping.

If you stopped some time ago and are now weighing your options, the question of what happens after stopping Wegovy long-term is answered there too. And if you want to understand how Wegovy compares to other licensed options (including tirzepatide) the weight-loss treatments overview sets out the landscape plainly.

For anyone considering starting Wegovy for the first time, or restarting after a gap, our prescribers carry out a same-day clinical review of every consultation, a named clinician, not a system, reads your answers. Start your free consultation at the treatment page.